Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 36: 362-366, 1990;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bowsher, R. R.
Right arrow Articles by Henry, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bowsher, R. R.
Right arrow Articles by Henry, D. P.

Clinical Chemistry, Vol 36, 362-366, Copyright © 1990 by American Association for Clinical Chemistry

Cross-reactivity of monomeric and dimeric biosynthetic human growth hormone in commercial immunoassays

RR Bowsher, JM Apathy, AL Ferguson, RM Riggin and DP Henry
Lilly Laboratory for Clinical Research, Eli Lilly & Co., Indianapolis, IN 46285.

Commercial kits give different measurements for concentrations of growth hormone (GH, somatotropin) in serum. Most notably, a two-site monoclonal-antibody-based immunoradiometric assay (IRMA) from Hybritech routinely yields lower values than do conventional RIAs in which polyclonal antibodies are used. We used purified dimeric biosynthetic human GH as a model compound to investigate the specificity of five commercial immunoassays for size variants of GH. In all five assays, biosynthetic monomeric GH was significantly more potent than pituitary- derived standard GH supplied with the kits. Dimeric GH was significantly less potent than monomer in four of the five assays, and cross-reactivities varied more than fivefold, from 15% to 84%. Using three commercial kits selected for their specificity for dimeric GH, we measured GH in serum samples from 18 normal adults. The mean GH concentrations in serum--0.7 (Hybritech, IRMA), 1.8 (Diagnostic Products, RIA), and 3.1 (Cambridge, RIA) micrograms/L--differed significantly, but in the same rank order as that obtained in the experiments on dimer cross-reactivity.


The following articles in journals at HighWire Press have cited this article:


Home page
 Eur J EndocrinolHome page
K. Pazaitou-Panayiotou, T. Kelesidis, I. Kelesidis, A. Kaprara, J. Blakeman, I. Vainas, A. Mpousoulegas, C. J Williams, and C. Mantzoros
Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer
Eur. J. Endocrinol., February 1, 2007; 156(2): 187 - 194.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. S. Kurland, F. K. W. Chan, C. J. Rosen, and J. P. Bilezikian
Normal Growth Hormone Secretory Reserve in Men with Idiopathic Osteoporosis and Reduced Circulating Levels of Insulin-Like Growth Factor-I
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2576 - 2579.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Association for Clinical Chemistry.